ALK and non-small cell lung carcinoma: Nevertheless, most of these studies precluded participants harbouring sensitive oncogene mutations including EGFR/ALK, and whether this combined regimen could benefit locally advanced oncogene-mutant NSCLC patients remains poorly explored.